GCP
AKCA

GSA Capital Partners’s Akcea Therapeutics Inc AKCA Stock Holding History

GSA Capital Partners’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,925
Closed -$280K – 1862
2019
Q2 		$280K Buy
+11,925
New +$295K 0.03% 1038

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

GSA Capital Partners's AKCA Position: Q3 2019 in Review

GSA Capital Partners sold out of Akcea Therapeutics Inc (AKCA) in Q3 2019, closing a stake of 11,925 shares — an estimated $280K sold.

GSA Capital Partners first reported a position in AKCA in Q2 2019 and held it in 1 quarter. The position peaked at $280K in Q2 2019. 62 funds tracked by Wall St. Rank hold AKCA as of Q3 2019.

  • GSA Capital Partners reported no remaining Akcea Therapeutics Inc position as of Q3 2019 after selling out during the quarter.
  • GSA Capital Partners sold 11,925 Akcea Therapeutics Inc shares in Q3 2019, an estimated $280K.
  • GSA Capital Partners first reported a position in Akcea Therapeutics Inc in Q2 2019 and held it in 1 quarter.
  • GSA Capital Partners's Akcea Therapeutics Inc position peaked at $280K in Q2 2019.
  • 62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2019.

Based on GSA Capital Partners's 13F filing for Q3 2019, filed 12 Nov 2019.